China: Healthcare

生物安全及人类遗传资源管理是医药企业开展研发、临床试验、生物制品生产及跨境科研合作时需要关注的重要合规领域。本文结合医药企业的主

China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting

Medical enterprises face critical decisions in trademark strategy and brand building, while healthcare professionals must maintain expertise in resuscitation techniques and emergency response protocols. These parallel challenges highlight the intersection of intellectual property protection in pharmaceuticals and the ongoing need for standardized medical training across institutions.

Chinese regulators intensified anti-corruption enforcement in the life sciences sector during 2026, with particular emphasis on medical insurance fraud, investigator-initiated studies, and patient programs.

China's role in the global pharmaceutical innovation market is undergoing a substantial shift.

自迈入2025年以来，伴随广告行业新业态、新模式、新技术的不断涌现，我国广告监管也迎来了体系化升级，从广告法系列执法指南的出台...

2022年4月11日，国家药品监督管理局（" 国家药监局"）发布了《药品年度报告管理规定》以及相应的报告模板（以下合称" 《年报规定》"）...

自国务院于2015年发布《关于改革药品医疗器械审评审批制度的意见》（国发〔2015〕44号）并启动药品医疗器械审评审批制度改革工作以来，我国不断߾

Since the General Office of the State Council issued the "Opinions on Promoting the Development of "Internet + Medical Health" on April 25...